About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Hemophilia Treatment Market Size, Global Trends, Top Share, Forecast to 2033
Hemophilia Treatment Market

Hemophilia Treatment Market Size, Share & Trends Analysis Report By Type (Hemophilia A, Hemophilia B), By Drug Therapy (Recombinant coagulation factor concentrates therapy, Plasma-derived coagulation factor concentrates therapy, Non-factor replacement therapy, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRHI55906DR
Author : Debashree Bora
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Hemophilia Treatment Market Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Hemophilia A
        1. By Value
      3. Hemophilia B
        1. By Value
    3. By Drug Therapy
      1. Introduction
        1. Drug Therapy By Value
      2. Recombinant coagulation factor concentrates therapy
        1. By Value
      3. Plasma-derived coagulation factor concentrates therapy
        1. By Value
      4. Non-factor replacement therapy
        1. By Value
      5. Others
        1. By Value
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Hemophilia A
        1. By Value
      3. Hemophilia B
        1. By Value
    3. By Drug Therapy
      1. Introduction
        1. Drug Therapy By Value
      2. Recombinant coagulation factor concentrates therapy
        1. By Value
      3. Plasma-derived coagulation factor concentrates therapy
        1. By Value
      4. Non-factor replacement therapy
        1. By Value
      5. Others
        1. By Value
    4. U.S.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Hemophilia A
          1. By Value
        3. Hemophilia B
          1. By Value
      2. By Drug Therapy
        1. Introduction
          1. Drug Therapy By Value
        2. Recombinant coagulation factor concentrates therapy
          1. By Value
        3. Plasma-derived coagulation factor concentrates therapy
          1. By Value
        4. Non-factor replacement therapy
          1. By Value
        5. Others
          1. By Value
    5. Canada
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Hemophilia A
        1. By Value
      3. Hemophilia B
        1. By Value
    3. By Drug Therapy
      1. Introduction
        1. Drug Therapy By Value
      2. Recombinant coagulation factor concentrates therapy
        1. By Value
      3. Plasma-derived coagulation factor concentrates therapy
        1. By Value
      4. Non-factor replacement therapy
        1. By Value
      5. Others
        1. By Value
    4. U.K.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Hemophilia A
          1. By Value
        3. Hemophilia B
          1. By Value
      2. By Drug Therapy
        1. Introduction
          1. Drug Therapy By Value
        2. Recombinant coagulation factor concentrates therapy
          1. By Value
        3. Plasma-derived coagulation factor concentrates therapy
          1. By Value
        4. Non-factor replacement therapy
          1. By Value
        5. Others
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Hemophilia A
        1. By Value
      3. Hemophilia B
        1. By Value
    3. By Drug Therapy
      1. Introduction
        1. Drug Therapy By Value
      2. Recombinant coagulation factor concentrates therapy
        1. By Value
      3. Plasma-derived coagulation factor concentrates therapy
        1. By Value
      4. Non-factor replacement therapy
        1. By Value
      5. Others
        1. By Value
    4. China
      1. By Type
        1. Introduction
          1. Type By Value
        2. Hemophilia A
          1. By Value
        3. Hemophilia B
          1. By Value
      2. By Drug Therapy
        1. Introduction
          1. Drug Therapy By Value
        2. Recombinant coagulation factor concentrates therapy
          1. By Value
        3. Plasma-derived coagulation factor concentrates therapy
          1. By Value
        4. Non-factor replacement therapy
          1. By Value
        5. Others
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Singapore
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Hemophilia A
        1. By Value
      3. Hemophilia B
        1. By Value
    3. By Drug Therapy
      1. Introduction
        1. Drug Therapy By Value
      2. Recombinant coagulation factor concentrates therapy
        1. By Value
      3. Plasma-derived coagulation factor concentrates therapy
        1. By Value
      4. Non-factor replacement therapy
        1. By Value
      5. Others
        1. By Value
    4. UAE
      1. By Type
        1. Introduction
          1. Type By Value
        2. Hemophilia A
          1. By Value
        3. Hemophilia B
          1. By Value
      2. By Drug Therapy
        1. Introduction
          1. Drug Therapy By Value
        2. Recombinant coagulation factor concentrates therapy
          1. By Value
        3. Plasma-derived coagulation factor concentrates therapy
          1. By Value
        4. Non-factor replacement therapy
          1. By Value
        5. Others
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Hemophilia A
        1. By Value
      3. Hemophilia B
        1. By Value
    3. By Drug Therapy
      1. Introduction
        1. Drug Therapy By Value
      2. Recombinant coagulation factor concentrates therapy
        1. By Value
      3. Plasma-derived coagulation factor concentrates therapy
        1. By Value
      4. Non-factor replacement therapy
        1. By Value
      5. Others
        1. By Value
    4. Brazil
      1. By Type
        1. Introduction
          1. Type By Value
        2. Hemophilia A
          1. By Value
        3. Hemophilia B
          1. By Value
      2. By Drug Therapy
        1. Introduction
          1. Drug Therapy By Value
        2. Recombinant coagulation factor concentrates therapy
          1. By Value
        3. Plasma-derived coagulation factor concentrates therapy
          1. By Value
        4. Non-factor replacement therapy
          1. By Value
        5. Others
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Hemophilia Treatment Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Pfizer Inc
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Novo Nordisk A/S
    3. Hoffmann-La Roche Ltd
    4. Bayer AG
    5. Shire
    6. CSL Behring
    7. Grifols, S.A
    8. Biogen Inc
    9. Sanofi S.A
    10. BioMarin Pharmaceutical Inc
    11. Octapharma AG
    12. Swedish Orphan Biovitrum AB
    13. Novartis AG
    14. Sangamo Therapeutics, Inc
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Hyperhidrosis Treatment Market Size The global hyperhidrosis treatment market size was valued at USD 1,611.31 million in 2022. It is projected to reach USD 2,307.33 million by 2031, growing at a CAGR of 4.07% during the forecast period (2023-2031).
Buy Now
Global Report
Lice Treatment Market Size The global lice treatment market size was valued at USD 1.12 billion in 2024, and it is projected to reach from USD 1.19 billion by 2025 to USD 1.95 billion by 2033, growing at a CAGR of 6.40% during the forecast peri
Buy Now
Global Report
The global mobile water treatment market size was worth USD 1806.1 million in 2021. It is predicted to reach an expected value of USD 4938.8 million by 2030, growing at a CAGR of 12.1% during the forecast period (2022–2030).
Buy Now
Global Report
Tendonitis Treatment Market Size The global tendonitis treatment market size was valued at USD 212.59 billion in 2024 and is anticipated to grow from USD 219.54 billion in 2025 to reach USD 284 billion in 2033, growing at a CAGR of 3.27% during the
Buy Now
Global Report
Global Uveitis Treatment Market Size The global uveitis treatment market size was valued at USD 2.28 billion in 2024 and is expected to grow from USD 2.48 billion in 2025 to reach USD 4.87 billion by 2033, growing at a CAGR of 8.8% during the f
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright . All rights Reserved.